Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIBC-II follow-up study in newborns with perinatal asphyxia
PACTR202505604153688Phase 2Recruiting
- Sponsor
- University of Kinshasa Hospital
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of 2-iminobiotin in asphyxia neonatorum (2 arms), sponsored by University of Kinshasa Hospital. Primary endpoint: Survival with normal outcome at 24 months. Started Aug 2024; status: recruiting.
02
Drugs
2-iminobiotin
03
Conditions
asphyxia neonatorum
Beyond the preview
Go deeper on PACTR202505604153688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202505604153688.